Is AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) a Buy? The Stock Reported Less Sellers

January 11, 2018 - By reb123z

The stock of AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) registered a decrease of 99.25% in short interest. AMBS’s total short interest was 200 shares in January as published by FINRA. Its down 99.25% from 26,700 shares, reported previously.

The stock increased 2.33% or $0.002 during the last trading session, reaching $0.099. About 472,694 shares traded. Amarantus Bioscience Holdings, Inc (OTCMKTS:AMBS) has 0.00% since January 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company has market cap of $6.76 million. The companyÂ’s diagnostic products in development include the lymphocyte proliferation test, a diagnostic blood test for AlzheimerÂ’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. It currently has negative earnings. The Company’s therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of ParkinsonÂ’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.

More notable recent Amarantus Bioscience Holdings, Inc (OTCMKTS:AMBS) news were published by: Globenewswire.com which released: “Amarantus Provides Update on Capital Restructuring and Announces Participation …” on January 09, 2018, also Marketwatch.com with their article: “Amarantus BioScience Holdings Inc.” published on June 30, 2011, Globenewswire.com published: “Amarantus Effects Capital Restructuring in Anticipation of National Exchange …” on May 22, 2015. More interesting news about Amarantus Bioscience Holdings, Inc (OTCMKTS:AMBS) were released by: Globenewswire.com and their article: “Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from US …” published on December 11, 2017 as well as Globenewswire.com‘s news article titled: “Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in …” with publication date: December 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.